Conventional approaches to identifying cancer targets are complicated by the chromosomal instability of tumour cells, and typically result in a large number of differentially expressed candidate genes with uncertain disease relevance. Here we present a novel approach which aims to elucidate the molecular changes that are induced after loss of tumour suppressor function. Using gene silencing tools, we mimic the loss of tumour suppressor function to identify key regulators of tumour initiation and progression. Loss of function of the tumour suppressor PTEN (phosphatase and tensin homologue deleted on chromosome 10) correlates with increased invasive cell growth due to the resulting chronic activation of the PI 3-kinase (phosphoinositide 3-kinase) pathway. Induced activation of PI 3-kinase either by inhibiting PTEN expression or by using p110*, a constitutively active PI 3-kinase, increased signalling and the invasive growth potential of cells. Using this unbiased approach we have identified novel downstream effectors of PI 3-kinase/PTEN signalling that mediate the behaviour of cells with a hyperactive PI 3-kinase pathway. These molecules represent candidate targets for therapeutic intervention in patients with PTEN-deficient tumours.
Introduction
Conventional approaches to identifying novel cancer targets have focused on comparing the differences in gene expression patterns between normal and tumour tissues [1, 2] . Due to the chromosomal instability of tumour cells, however, frequently a large number of differentially expressed genes are obtained, which need to be examined for their disease relevance. Therefore we chose to take an alternative approach by analysing the process of molecular changes induced after loss of tumour suppressor function instead of comparing disease endpoints. This is accomplished by induced inhibition of tumour suppressor expression using either GB (GeneBloc) antisense molecules or synthetic as well as vector-expressed siRNA (small interfering RNA) molecules. With this unbiased loss of function approach, we intend to identify key molecules involved in the early and later phases of tumour progression after the loss of tumour suppressor function.
One of our model systems is the PI 3-kinase (phosphoinositide 3-kinase)/PTEN (phosphatase and tensin homologue deleted on chromosome 10) signalling pathway, which regulates a diverse set of proliferative responses. PI 3-kinase is normally very transiently activated after growth factor stimulation of cells [3, 4] , and regulates proliferation, survival, motility and glucose transport [5] [6] [7] . The tumour suppressor PTEN functions as a negative regulator of PI 3-kinase and thereby ensures that activation of the pathway occurs in a transient and controlled fashion [8] . Loss of PTEN leads to chronic activation of the PI 3-kinase pathway, and correlates with increased metastatic behaviour of late-stage human tumours [9, 10] . Our goal is not to interfere with responses that are required for normal cell function, but rather to inhibit effectors downstream of activated PI 3-kinase that mediate processes such as motility or metastasis. These effectors may represent suitable targets for therapeutic intervention in PTEN-defective tumours.
Tools
Gene silencing tools such as antisense or siRNA molecules have been used primarily for inhibitory responses, with the potential caveat that negative readouts are more prone to artefacts imposed by the reagents or the conditions used [11] . Therefore we wanted to establish a positive readout such as increased PI 3-kinase signalling first, in order to feel confident in studying inhibitory effects mediated by gene silencing reagents.
We set out to mimic loss of PTEN function and its early molecular consequences by transiently inhibiting its expression using GBs, which represent antisense molecules of the third generation [12] . We reasoned that if expression of the inhibitor PTEN is inhibited successfully, then an increase in the activation status of downstream effectors, such as Akt (also known as protein kinase B), should be observed. Knockdown of PTEN expression by more than 90% was achieved for several days under conditions where cells continued to proliferate. GB-mediated PTEN knockdown indeed resulted in increased activation of Akt, and was consistently achieved with three different PTEN-specific GB molecules. The corresponding four-nucleotide mismatch control oligonucleotides had no effect. The Akt activation achieved was dependent on PI 3-kinase and appeared to be functional, since PTEN GB-treated cells exhibited increased resistance against apoptotic stimuli [12] . Furthermore, the Akt substrates GSK3α (glycogen synthase kinase 3α) and FKHRL1, a forkhead family transcription factor, showed increased phosphorylation, indicating not only that one of the immediate PI 3-kinase effectors is activated, but that the signal is successfully transmitted further downstream (A. Klippel, unpublished work). Subsequently, we proved that it is also possible to inhibit chronic activation of PI 3-kinase by GB-mediated down-regulation of the catalytic subunit of PI 3-kinase, p110. In the course of these studies we found that distinct isoforms of p110 appeared to be predominant for PI 3-kinase signalling in different cell types [12, 13] . Taken together, these experiments show that induced inhibition of PTEN expression can successfully mimic the early molecular changes that occur after loss of tumour suppressor function. In addition, we can effectively interfere with activated PI 3-kinase using this method. Recently, we have successfully applied this induced loss of function approach to another tumour suppressor system, the transforming growth factor-β signalling pathway [14] .
We have extended our repertoire of knockdown tools with siRNA/shRNA (short hairpin RNA) molecules, which have the advantage that they can also be expressed from vectors [13, 15] . Vector-derived stable expression of shRNAs provides a more continuous knockdown of gene expression compared with the transient transfection of synthetic antisense or siRNA molecules. However, the use of siRNA for studies that require several rounds of cell division in less robust cell systems has been hampered in some cases by stress or apoptotic responses. This might be caused by interferon as well as microRNA-directed responses [16] [17] [18] . Therefore the application of siRNA to target validation requires a careful selection of conditions and appropriate controls. To be able to inhibit the expression of proteins that are required for basic cellular functions, such as proliferation and survival, we have now established viral and non-viral vectors that direct shRNA expression in an inducible manner ( [15] ; and results not shown). This facilitates the isolation of stable cell populations in the absence of negative selective pressure and without the problem of clonal variation. We can use the inducible shRNA system not only to validate candidate effector targets of a hyperactive PI 3-kinase pathway in cell-based systems, but also to validate their function in mouse models for metastasis [15] .
An inducible version of a constitutively active PI 3-kinase, p110
* , serves as an additional tool to chronically activate PI 3-kinase signalling [19] , and acts as a control for GB-and siRNA-induced effects. The inducible p110 * allows us to study the effects of a hyperactive PI 3-kinase pathway on invasive cell growth in the absence or presence of other growth factor-induced signals, and to determine whether chronic activation of PI 3-kinase is necessary or even sufficient to induce a signalling response or expression of a target in cells with increased invasive potential. The use of an inducible p110
* circumvents problems typically associated with transient or stable expression systems and provides an unbiased analysis of PI 3-kinase effects (see above and [19] ).
Assay system
Using inducible variants of p110 * , we and others have shown previously that cells with an activated PI 3-kinase pathway exhibit an increased ability to grow in an anchorageindependent fashion [19, 20] . PTEN knockout embryonic stem cells are also able to grow in semi-solid matrices [21] . Recently, we demonstrated that tumour cells in which the PI 3-kinase pathway was chronically activated by either induced inhibition of PTEN expression or p110 * activation acquired a growth advantage on Matrigel [12] . Matrigel is an extracellular matrix-containing basement membrane that facilitates growth of cells with increased malignant potential [22] [23] [24] . These results demonstrate that both independent methods to activate PI 3-kinase signalling can successfully simulate the effects of loss of function of PTEN.
In contrast with what we observe on Matrigel, we have not been able to detect substantial differences in the behaviour of cells grown on tissue culture plastic in response to activation of PI 3-kinase. Similarly, the growth of PTENdeficient metastatic prostate tumour PC-3 cells on plastic is only marginally affected upon inhibition of PI 3-kinase using the small-molecule inhibitor LY294002 (Figure 1 ): the cells appear flatter with a less refractile morphology and continue to grow. In contrast, growth of this cell line with a hyperactive PI 3-kinase pathway [12] on Matrigel was severely impaired in the presence of LY294002, which indicates that a chronically active PI 3-kinase might primarily affect growth in three-dimensional cultures. The difference in the PI 3-kinase dependence between growth on plastic and on Matrigel is only observed when LY294002 is titrated down to the lowest possible efficacious concentration for inhibiting PI 3-kinase activity (3 µM for PC-3 cells, as monitored for example by Akt phosphorylation). In many studies substantially higher concentrations of LY294002 have been used, which results in growth arrest or even apoptosis. High LY294002 concentrations are likely to cause secondary effects, such as inhibition of mTOR (mammalian target of rapamycin) and other molecules with similiarity to PI 3-kinase [7, 25] . Taken together, our results suggest that growth on Matrigel provides a suitable in vitro assay system with which to analyse the increased growth potential of cells with an activated PI 3-kinase pathway.
Identification of novel cancer targets in cells with activated PI 3-kinase
We used the approach outlined above to modulate the growth potential of cells in vitro. A PTEN-positive human cancer cell line with low metastatic potential exhibited enhanced growth on Matrigel after activation of PI 3-kinase signalling either through PTEN-GB treatment or by inducing p110 * activity (Figure 2A, left-hand panels) . In contrast, PTEN-defective tumour cells which form metastases in a nude mouse model grow well on Matrigel without further stimulation of the pathway. In this case we can simulate PTEN function by inhibiting PI 3-kinase either by using LY294002 treatment or by GB-mediated inhibition of p110 expression. Both treatments strongly inhibited growth on Matrigel (Figure 2A, right-hand panels) . Subsequently, we performed gene expression array analysis of RNA isolated from these cells grown on Matrigel to identify genes that become deregulated in response to chronically activated PI 3-kinase. We performed pairwise comparisons between samples in which the PI 3-kinase pathway was switched on and samples in which this pathway was turned off, as shown in Figure 2(B) . In the course of the analysis we varied parameters such as treatment, time point and cell systems, and looked for overlapping patterns. This approach leads to a rather well defined fraction of genes that are differentially expressed, and therefore requires minimal bioinformatic effort. We routinely verify the differential expression pattern of candidate genes by real-time reverse transcription-PCR. Genes that exhibit differential expression in a time-course analysis are considered for further validation in cell-based assays. Figure 3 gives an example of how such candidate targets are validated in PTEN-defective metastatic PC-3 cells using GBs and the Matrigel assay. The upper two sets of panels are control treatments, which are performed in each experiment. PTEN-GB treatment has no effect on growth on Matrigel, because these cells lack PTEN. In contrast, inhibiting expression of the catalytic subunit of PI 3-kinase, p110 (p110β for PC-3 cells), strongly reduced growth on Matrigel. In parallel, GBs are tested that inhibit expression of candidate target genes (Figure 3 , lower panels). The result for two molecules representing two classes of downstream effectors are shown. The first class of molecules has no loss of function phenotype in the Matrigel assay despite PI 3-kinasedependent expression. The second class of molecules appear to be required for growth on Matrigel, as GB-mediated reduction of expression interfered with growth on basement membrane matrix. We use at least two different sets of GBs with corresponding mismatch derivatives per target. This second class is functionally validated by this assay as downstream effectors of PI 3-kinase/PTEN signalling with the potential to mediate the invasive-like cell growth. Next, we confirm these results by repeating the validation experiments using a second independent gene silencing tool such as siRNA or expressed shRNA [13] . More recently we have used inducible shRNA expression vectors to functionally validate candidate targets in an orthotopic prostate cancer model [15] . Human prostate tumour cells containing stably integrated inducible target-directed shRNA vectors are implanted intra-prostatically in immune-deficient mice. The animals are split into two groups; one group is treated to induce shRNA expression, whereas the control group is mock-treated, and primary tumour growth and (PTEN −/− ) cells were grown in the presence of DMSO or LY294002 on Matrigel as described for Figure 1 . In parallel, PC-3 cells treated with p110-GB or its corresponding mismatch control GB were analysed. (B) RNA extracted from cells grown on Matrigel was subjected to gene expression array analysis. Differences in expression patterns were determined by comparing pairs of matching cell samples with activated and inhibited PI 3-kinase signalling as indicated in (A). Overlapping patterns of genes that were differentially expressed in several distinct pairs were selected and considered for further investigation.
metastasis formation are monitored. Molecules that pass the series of validation tests described above represent potential targets for therapeutic intervention in tumours with an activated PI 3-kinase pathway.
Using the outlined approach, we have identified and validated novel candidate effectors downstream of activated PI 3-kinase in cell-based assays and mouse tumour models. A number of these novel effector proteins are currently being characterized further for their ability to mediate invasive signalling. These molecules appear to link increased PI 3-kinase signalling to cellular responses such as migration, hypoxia, mitochondrial dynamics and glycolysis, and will aid in dissecting this important signalling pathway.
